A case of VEXAS syndrome associated with EBV-associated hemophagocytic lymphohistiocytosis

Blood Cells Mol Dis. 2022 Mar:93:102636. doi: 10.1016/j.bcmd.2021.102636. Epub 2021 Nov 30.

Abstract

Vacuoles, E1, X-linked, autoimmunity, somatic (VEXAS) syndrome is characterized by a pathogenic mutation in UBA1, which leads to protean complications including autoimmunity and myelodysplasia. A 56-year-old man with steroid-dependent, later steroid-refractory cutaneous polyarteritis nodosa and Sweet syndrome developed recurrent daily fever, macrocytic anemia, thrombocytopenia, acute hypoxic respiratory failure, and anasarca. He was eventually diagnosed with Epstein-Barr virus (EBV) viremia and hemophagocytic lymphohistiocytosis (HLH). He improved clinically with rituximab, ruxolitinib, and increased glucocorticoids before expiring from Pseudomonas sepsis. UBA1 exon 3 mutational analysis in myeloid enriched peripheral blood revealed a c.122T>C (p.Met41Thr) pathogenic variant, consistent with VEXAS syndrome. We describe the first case of EBV-associated HLH in a patient diagnosed with VEXAS syndrome. Early identification of this syndrome will be important in order to offer potential therapies before life-threatening complications arise.

Keywords: Epstein-Barr virus; Hemophagocytic lymphohistiocytosis; Polyarteritis nodosa; Sweet syndrome; UBA1; Ubiquitin-proteasome system; VEXAS syndrome.

Publication types

  • Case Reports

MeSH terms

  • Epstein-Barr Virus Infections* / complications
  • Epstein-Barr Virus Infections* / drug therapy
  • Herpesvirus 4, Human
  • Humans
  • Lymphohistiocytosis, Hemophagocytic* / complications
  • Lymphohistiocytosis, Hemophagocytic* / diagnosis
  • Lymphohistiocytosis, Hemophagocytic* / drug therapy
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes*
  • Rituximab

Substances

  • Rituximab